In vitro drug sensitivity in canine lymphoma

Open access

Abstract

Introduction: Due to the high heterogeneity of canine lymphoma, the aim of the present study was to test in vitro the chemosensitivity of canine high-grade primary lymphoma cells to various cytostatic drugs commonly used to treat dogs: 4-HO-cyclophosphamide, doxorubicin, dexamethasone, prednisolone, vincristine, etoposide, chlorambucil, lomustine, and cytosine arabinoside. Material and Methods: To determine the cell viability and drug ability to induce apoptosis two different tests were used: an MTT assay and annexin V/propidium iodide staining. Results: Both in vitro tests were found to be useful tools. Significant differences in the sensitivity, depending on the drug type, between B-, T- and mixed/null-type lymphoma cells were found for the majority of the tested drugs. B-type cells were the most sensitive in vitro, whereas T-type cells seemed to be the most resistant. Doxorubicin, chlorambucil, etoposide, and vincristine most strongly reduced the cell viability and induced apoptosis. Conclusion: In vitro assays, such as the MTT test and especially the annexin V/PI assay, may be useful tools for predicting a response to the treatment of high-grade lymphoma in dogs or improving the treatment outcomes in individual animals.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Den Boer M.L. Harms D.O. Pieters R. Kazemier K.M. Gobel U. Körholz D. Graubner U. Haas R.J. Jorch N. Spaar H.J. Kaspers G.J. Kamps W.A. Van der Does-Van den Berg A. Van Wering E.R. Veerman A.J. Janka-Schaub G.E.: Patient stratification based on prednisolone-vincristineasparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003 21 262-3268.

  • 2. Escherich G. Tröger A. Göbel U. Graubner U. Pekrun A. Jorch N. Kaspers G. Zimmermann M. zur Stadt U. Kazemier K. Pieters R. Den Boer M.L. Horstmann M. Janka G.E.: The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97). Haematologica 2011 96 854-862.

  • 3. Fedele C. Tothill R.W. McArthur G.A.: Navigating the challenge of tumor heterogeneity in cancer therapy. Cancer Discov 2014 4146-148.

  • 4. Gaurnier-Hausser A. Patel R. Baldwin A.S. May M.J. Mason N.J.: NEMO-binding domain peptide inhibits constitutive NF-kappaB activity and reduces tumor burden in a canine model of relapsed refractory diffuse large B-cell lymphoma. Clin Cancer Res 2011 17 4661-4671.

  • 5. Hatok J. Babusikova E. Matakova T. Mistuna D. Dobrota D. Racay P.: In vitro assays for the evaluation of drug resistance in tumor cells. Clin Exp Med 2009 9 1-7.

  • 6. Ito D. Frantz A.M. Modiano J.F.: Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. Vet Immunol Immunopathol 2014 24 16.

  • 7. Ito D. Frantz A.M. Williams C. Thomas R. Burnett R.C. Avery A.C. Modiano J.F.: CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies. Leuk Lymphoma 2012 53 1390-1398.

  • 8. Kaspers G.J. Pieters R. Van Zantwijk C.H. De Laat P.A. De Waal F.C. Van Wering E.R. Veerman A.J.: In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. Br J Cancer 1991 64 469-474.

  • 9. Kitada S. Andersen J. Akar S. Zapata J.M. Takayama S. Krajewski S. Wang H.G. Zhang X. Bullrich F. Croce C.M. Rai K. Hines J. Reed J.C.: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998 91 3379-3389.

  • 10. Marconato L.: The staging and treatment of multicentric highgrade lymphoma in dogs: a review of recent developments and future prospects. Vet J 2011 188 34-38.

  • 11. Marconato L. Gelain M.E. Comazzi S.: The dog as a possible animal model for human non-Hodgkin lymphoma: a review. Hematol Oncol 2013 31 1-9.

  • 12. Matsuda A. Tanaka A. Muto S. Ohmori K. Furusaka T. Jung K. Karasawa K. Okamoto N. Oida K. Itai A. Matsuda H.: A novel NF-kappaB inhibitor improves glucocorticoid sensitivity of canine neoplastic lymphoid cells by up-regulating expression of glucocorticoid receptors. Res Vet Sci 2010 89 378-382.

  • 13. Mosmann T.: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983 65 55-63.

  • 14. Pawlak A. Rapak A. Drynda A. Poradowski D. Zbyryt I. Dzimira S. Suchański J. Obmińska-Mrukowicz B.: Immunophenotypic characterization of canine malignant lymphoma: a retrospective study of cases diagnosed in Poland Lower Silesia over the period 2011-2013. Vet Comp Oncol 2014 doi: 10.1111/vco.12112.

  • 15. Pawlak A. Rapak A. Zbyryt I. Obminska-Mrukowicz B.: The effect of common antineoplastic agents on induction of apoptosis in canine lymphoma and leukemia cell lines. In Vivo 2014 28 843-850.

  • 16. Pieters R. Huismans D.R. Loonen A.H. Hählen K. van der Does-van den Berg A. van Wering E.R. Veerman A.J.: Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 1991 338 399-403.

  • 17. Price G.S. Page R.L. Fischer B.M. Levine J.F. Gerig T.M.: Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma. J Vet Intern Med 1991 5 259-262.

  • 18. Seiser E.L. Thomas R. Richards K.L. Kelley M.K. Moore P. Suter S.E. Breen M.: Reading between the lines: molecular characterization of five widely used canine lymphoid tumour cell lines. Vet Comp Oncol 2013 11 30-50.

  • 19. Styczynski J. Wysocki M.: Is the in vitro drug resistance profile the strongest prognostic factor in childhood acute lymphoblastic leukemia? J Clin Oncol 2004 5 963-964.

  • 20. Vaughan A. Johnson J.L. Williams L.E.: Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol. J Vet Intern Med 2007 21 1332-1339.

  • 21. Zandvliet M. Teske E. Schrickx J.A.: Multi-drug resistance in a canine lymphoid cell line due to increased P-glycoprotein expression a potential model for drug-resistant canine lymphoma. Toxicol In Vitro 2014 28 1498-1506.

Search
Journal information
Impact Factor

IMPACT FACTOR J Vet Res 2018: 0.829
5-year IMPACT FACTOR: 0.938

CiteScore 2018: 0.68

SCImago Journal Rank (SJR) 2018: 0.291
Source Normalized Impact per Paper (SNIP) 2018: 0.501

Cited By
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 216 71 5
PDF Downloads 131 58 3